All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Impact of immunotherapy on Real-world survival outcomes in metastatic renal cell carcinoma.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27283933%3A_____%2F23%3AN0000003" target="_blank" >RIV/27283933:_____/23:N0000003 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/23:10471047 RIV/00216208:11110/23:10471047 RIV/00216208:11140/23:10471047 RIV/61989592:15110/23:73621206 and 8 more

  • Result on the web

    <a href="https://link.springer.com/article/10.1007/s11523-023-01013-0" target="_blank" >https://link.springer.com/article/10.1007/s11523-023-01013-0</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s11523-023-01013-0" target="_blank" >10.1007/s11523-023-01013-0</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Impact of immunotherapy on Real-world survival outcomes in metastatic renal cell carcinoma.

  • Original language description

    "Background: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. Objective: The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. Methods: RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. Results: The median overall survival from the initiation of first-line treatment was 24.5 months versus not reached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. Conclusion: In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors."

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    <a href="/en/project/NU21-03-00539" target="_blank" >NU21-03-00539: The effect of endoplasmic reticulum stress on the immune status of tumors and the efficiency of immunotherapy in the treatment of ovarian and renal cell carcinoma</a><br>

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Targeted Oncology

  • ISSN

    1776-2596

  • e-ISSN

    1776-260X

  • Volume of the periodical

    18

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    11

  • Pages from-to

    893-903

  • UT code for WoS article

    001104868200001

  • EID of the result in the Scopus database

    2-s2.0-85176434025